Cargando…

Sensitivity and specificity of the macimorelin test for diagnosis of AGHD

OBJECTIVE: The macimorelin test is approved for the diagnosis of adult growth hormone deficiency (AGHD) based on its efficacy vs the insulin tolerance test (ITT). Macimorelin has a significant advantage over ITT in avoiding hypoglycemia. Analyses were conducted to determine whether macimorelin perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Jose M, Biller, Beverly M K, Korbonits, Márta, Popovic, Vera, Luger, Anton, Strasburger, Christian J, Chanson, Philippe, Swerdloff, Ronald, Wang, Christina, Fleming, Rosa Rosanna, Cohen, Fredric, Ammer, Nicola, Mueller, Gilbert, Kelepouris, Nicky, Strobl, Frank, Ostrow, Vlady, Yuen, Kevin C J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923131/ https://www.ncbi.nlm.nih.gov/pubmed/33320108 http://dx.doi.org/10.1530/EC-20-0491

Ejemplares similares

OR32-4 Diagnostic Performance of Macimorelin vs the Insulin Tolerance Test (ITT) in 140 Patients at Varying Growth Hormone (GH) Cutpoints: A Post Hoc Analysis
por: Garcia, Jose, et al.
Publicado: (2019)

SAT-428 Effect of Age, Body Mass Index, and Sex on the Performance of Macimorelin for the Diagnosis of Adult Growth Hormone Deficiency: A Post Hoc Analysis
por: Garcia, Jose, et al.
Publicado: (2019)

Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants
por: Lissy, Michael, et al.
Publicado: (2020)

OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency
por: Garcia, Jose, et al.
Publicado: (2019)

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
por: Höybye, Charlotte, et al.
Publicado: (2022)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers
por: Urwyler, Sandrine A., et al.
Publicado: (2021)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency
por: Garcia, J. M., et al.
Publicado: (2013)

Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia
por: Herodes, Megan, et al.
Publicado: (2023)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

THU058 Impact Of A Smartphone App On Follow-up Of Adult Growth Hormone Deficiency (AGHD) Patients: Results From The Management Of AGHD (MAGHD) Study
por: De Vincentis, Sara, et al.
Publicado: (2023)

Macimorelin Acetate for the Diagnosis of Childhood-onset Growth Hormone Deficiency
por: Henry, Rohan K
Publicado: (2022)

Sexual Dysfunction: A Neglected and Overlooked Issue in Adult GH Deficiency: The Management of AGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2021)

Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program
por: Miller, Bradley S., et al.
Publicado: (2020)

SUN-301 Importance of Sexual Function Assessment in Multidimensional Evaluation of AGHD Patients: Results from the MAGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2020)

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
por: Biller, Beverly M K, et al.
Publicado: (2023)

SAT-282 Outcomes in Children Treated with Growth Hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS)
por: Angulo, Moris, et al.
Publicado: (2019)

THU008 Coverage Of Education And Training Of Traumatic Brain Injury-induced Growth Hormone Deficiency In US Endocrinology Fellowship Programs
por: Ji Yuen, Kevin Choong, et al.
Publicado: (2023)

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
por: Brod, Meryl, et al.
Publicado: (2018)

The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults: Data from: Glucacop, Macicop, and CARGO study
por: Atila, Cihan, et al.
Publicado: (2022)

Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program
por: Rapaport, Robert, et al.
Publicado: (2018)

Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion
por: Stojanovic, Marko, et al.
Publicado: (2019)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

SAT-LB11 Adult Growth Hormone Deficiency Transition Care From Pediatric to Adult Services: Insights From a US Advisory Board
por: Yuen, Kevin C J, et al.
Publicado: (2020)

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults
por: Strasburger, Christian J, et al.
Publicado: (2016)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

La octava maravilla
por: Kociancich, Vlady
Publicado: (1982)

El templo de las mujeres /
por: Kociancich, Vlady
Publicado: (1996)

Abisinia /
por: Kociancich, Vlady
Publicado: (1985)

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database
por: Kelepouris, Nicky, et al.
Publicado: (2019)

Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective
por: Hoffman, Andrew R, et al.
Publicado: (2022)

Los cuadernos de Vlady /
por: Vlady, 1920-2005
Publicado: (1985)

Abrir los ojos para soñar /
por: Vlady, 1920-2005
Publicado: (1996)

Los bajos del temor
por: Kociancich, Vlady 1941-
Publicado: (1992)

El templo de las mujeres
por: Kociancich, Vlady 1941-
Publicado: (1996)

A Long-Acting Human Growth Hormone With Delayed Clearance (VRS-317): Results of a Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Growth Hormone–Deficient Adults
por: Yuen, Kevin C. J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_01h58ndenoujn38ogqvc8eq5ai